E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Skull base surgery for the prevention of postoperative cerebrospinal fluid (CSF) leaks |
Sutura della dura madre per la prevenzione delle perdite postoperatorie di liquido cerebrospinale (LCS) in pazienti sottoposti a chirurgia della base del cranio |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10064518 |
E.1.2 | Term | Cranial operation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to demonstrate superiority of TachoSil compared to current practice as an adjunct in sealing the dura mater. The efficacy of the dura mater sealing must be evaluated postoperatively. |
Lâobiettivo primario e di dimostare la superiorita` di TachoSil in confronto alle tecniche correntemente utilizzate nella sutura della dura madre. Lâefficacia della sutura della dura madre sara` valutata nel post operatorio. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to evaluate the safety of TachoSil as an adjunct in sealing the dura mater. |
Lâobiettivo secondario e` quello di valutare la sicurezza di TachoSil come coadiuvante della sutura della dura madre. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Key inclusion criteria â positive response required for inclusion: ⢠Is the surgical approach/procedure consistent with skull base surgery? I.e. one of the following: a. Lateral approach to the foramen magnum: Far lateral, extreme lateral, anterolateral, posterolateral b. Approach to the jugular foramen: Infratemporal, juxta condylar, transjugular c. Approach to the cerebello pontine (CP) angle and petrous apex retrosigmoid, translabyrinthine, retrolabyrinthine, transcochlear (limited transpetrosal) d. Approach to the middle fossa: Subtemporal (+/- petrous apex drilling), pterional approach (any fronto temporal approach +/- orbitozygomatic deposition) e. Approach to the anterior fossa: Subfrontal (uni or bilateral) f. Approach to the midline posterior fossa For a complete list of inclusion criteria, please refer to the study protocol. |
Principali criteri di inclusione â e` richiesta una risposta positiva: ⢠Lâapproccio chirurgico/la procedura chirurgica e` compatibile con la chirurgia della base del cranio? Ad esempio uno dei seguenti: a. Approccio laterale al grande foro occipitale: molto laterale, estremamente laterale, anterolaterale, posterolaterale, b. Approccio al forame giugulare: infratemporale, iuxta condiloideo, transgiugulare, c. Approccio allâangolo ponto-cerebellare (CP) e allâapice petroso per via retrosigmoidea, translabirintica, retrolabirintica, transcocleare (transpetrosa limitata), d. Approccio alla fossa media: subtemporale (+/- trapanatura dell`apice petroso), approccio pterionale (qualsiasi approccio fronto-temporale +/- deposito orbito-zigomatico), e. Approccio alla fossa anteriore: subfrontale (monolaterale o bilaterale), f. Approccio alla fossa posteriore nella linea mediana. Per una lista completa dei criteri di inclusione, fare riferimento al protocollo di studio. |
|
E.4 | Principal exclusion criteria |
Key exclusion criteria â negative response required for inclusion: ⢠Has the patient been subject to neurosurgery within the last 3 months? ⢠Is the patient anticipated to undergo any additional neurosurgery which may affect the efficacy evaluation (e.g. re-operation or anticipation to undergo several neurosurgeries) before the Efficacy Follow-up Week 7±1 week? ⢠Is the patient anticipated to undergo any additional neurosurgery which may affect the safety evaluation (e.g. re-operation or anticipation to undergo several neurosurgeries) before the Safety Follow-up Week 28±2 weeks? ⢠The surgical approach/procedure is consistent with any transcranial or transfacial or combination of transcranial â transfacial approaches with wide defect in the skull base? I.e. any of the following: g. Trans basal approach h. Total petrosectomy i. Trans facial approach j. Trans sphenoidal approach k. Endoscopic procedures l. Trans oral approach (and any extension: Le Fort, mandibulotomy) ⢠Does the patient have more than one dura lesion (not including dura lesions from extraventricular or lumbar drains)? For a complete list of exclusion criteria, please refer to the study protocol. |
Principali criteri dâesclusione â e` richiesta una risposta negativa: ⢠Il paziente e` stato sottoposto a neurochirurgia negli ultimi 3 mesi? ⢠E` previsto che il paziente sia sottoposto a qualsisi ulteriore neurochirurgia che possa avere effetto sulla valutazione di efficacia (ad esempio re-intervento o in attesa di sottoporsi a piu` interventi di neurochirurgia) prima del follow-up sulla sicurezza (Settimana 28 ± 2 settimane)? ⢠Lâapproccio chirurgico/la procedura chirurgica e` compatibile con qualsiasi approccio transcraniale o transfacciale o la combinazione di approccio transcraniale \ transfacciale con ampio difetto dalla chirurgia della base del cranio? Ad esempio uno o piu` dei seguenti: g. Approccio transbasale, h. Petrosectomia totale, i. Approccio transfacciale, j. Approccio transfenoidale, k. Procedure endoscopiche, l. Approccio transorale (e qualsiasi estensione: Le Fort, mandibulotomia). ⢠Il paziente ha piu` di una lesione della dura (escluso lesioni della dura da drenaggio extraventricolare o lombare)? Per una lista completa dei criteri di esclusione, fare riferimento al protocollo di studio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint must be considered as reached if a clinically evident CSF- leak or a clinically evident pseudomeningocele has occurred post-operatively and until Efficacy Follow-up (week 7±1) or if treatment failure has occurred. |
Lâendpoint primario deve essere considerato raggiunto se si e` verificata unâevidenza clinica di perdita di liquido cerebrospinale (LCS) o unâevidenza clinica di pseudomeningocele nel postoperatorio fino alla Visita di follow-up di efficacia (settimana 7±1) o se si e` verificato il fallimento della terapia |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
correnti tecniche utilizzate x sutura dura madre |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 40 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Ultima visita dell'ultimo paziente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 22 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 22 |
E.8.9.2 | In all countries concerned by the trial days | 0 |